Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech gene therapy companies are viable as independent firms, Cell Genesys exec tells BIO.

Executive Summary

INDEPENDENT BIOTECH GENE THERAPY COMPANIES ARE VIABLE despite the recent wave of acquisitions of gene therapy research firms by large pharmaceutical companies, Cell Genesys Director of Business Development Bruce Hironaka told the Biotechnology Industry Organization annual meeting in Philadelphia June 12. Noting a string of recent mergers (Sandoz/SyStemix, Sandoz/Genetic Therapy, Inc., Schering-Plough/Canji, Rhone-Poulenc Rorer/Applied Immune Sciences and Chiron/Viagene), Hironaka observed: "This raises the question, can an independent gene therapy company make it?" Cell Genesys "believes the answer is yes, but the road will be a difficult one."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel